MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Alvotech SA

Deschisă

SectorSănătate

8.1 -1.34

Rezumat

Modificarea prețului

24h

Curent

Minim

8.06

Maxim

8.44

Indicatori cheie

By Trading Economics

Venit

-56M

-67M

Vânzări

48M

151M

EPS

-0.24

Marjă de profit

-44.289

Angajați

1,012

EBITDA

-258M

-120M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+139.23% upside

Dividende

By Dow Jones

Următoarele câștiguri

20 mai 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-976M

2.5B

Deschiderea anterioară

9.44

Închiderea anterioară

8.1

Alvotech SA Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

15 apr. 2025, 14:54 UTC

Câștiguri

Why Johnson & Johnson Stock Is Down After Earnings Beat Expectations -- Barrons.com

7 mai 2024, 20:30 UTC

Top știri

Teva Earnings Are Soon. What Could Keep the Stock Gains Going. -- Barrons.com

Comparație

Modificare preț

Alvotech SA Așteptări

Obiectiv de preț

By TipRanks

139.23% sus

Prognoză pe 12 luni

Medie 20 USD  139.23%

Maxim 28 USD

Minim 14 USD

În baza a 3 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruAlvotech SA - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

3 ratings

2

Cumpărare

1

Păstrare

0

Vânzare

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Alvotech SA

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.